Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and IMA950 Vaccine for Relapsing Glioblastoma
NCT03665545Phase 2Completed
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, IMA950 in glioblastoma (GBM). Started Oct 2018; status: completed.
02
Drugs
pembrolizumabIMA950
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03665545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665545.